$4.37
+0.08 (+1.86%)
Open$4.31
Previous Close$4.29
Day High$4.43
Day Low$4.20
52W High$23.43
52W Low$2.90
Volume—
Avg Volume278.1K
Market Cap29.18M
P/E Ratio—
EPS$-2.50
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+169.3% upside
Current
$4.37
$4.37
Target
$11.77
$11.77
$8.46
$11.77 avg
$14.40
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.64M | 35.79M | 31.57M |
| Net Income | -49,981,707 | 827.5K | 932.2K |
| Profit Margin | -429.4% | 2.3% | 3.0% |
| EBITDA | -33,162,477 | 1.82M | 1.58M |
| Free Cash Flow | — | 629.7K | 483.5K |
| Rev Growth | +187.2% | +6.8% | +6.0% |
| Debt/Equity | 0.19 | 0.61 | 0.73 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |